Immunocytokines: a novel class of potent armed antibodies.
about
Trial WatchInterleukin-7 and interleukin-15 for cancerInterleukin 12: still a promising candidate for tumor immunotherapy?The development of immunoconjugates for targeted cancer therapyHigh efficiency cell-specific targeting of cytokine activityThe extracellular matrix: Tools and insights for the "omics" eraCytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.Trial watch: Immunostimulatory cytokines in cancer therapy.Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.A highly functional synthetic phage display library containing over 40 billion human antibody clones.Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.Introduction to monoclonal antibodies.Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor siteThe antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.Immunocytokines for cancer treatment: past, present and future.Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.Designing immunoconjugates for cancer therapy.Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Immunocytokines: a review of molecules in clinical development for cancer therapy.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Single-domain antibodies for biomedical applications.Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.Demystifying the cytokine network: Mathematical models point the way.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins.
P2860
Q24618653-FED37F76-28A3-4749-859F-A59EDEC8824AQ26830709-672B71D7-BFFF-41B1-97D9-FC2C1D33A740Q26861559-6BDF963F-877C-41E3-922E-97C710E6CDBBQ27021990-12C36087-23BD-45B9-AD67-AA6D3449EE03Q28305410-2126EF02-D63A-4793-8A73-25627CA6BA8DQ28831183-BC3BBB05-8D80-4BE9-89D4-78CD7D92A1D0Q30381154-85EEE4B6-6393-429A-8EB3-68F920E49037Q30564779-378C5CAB-04D7-4F85-93F2-BBD21E47E518Q33880165-E699F3AA-278C-4680-94F2-F97258D340D3Q34223872-EB90DB96-6168-419E-892D-BA07C1B53F55Q34469107-4358E624-24EE-41A5-A42A-33EE52A8B985Q34684399-1722E777-DCB4-4C5C-8131-F73173EC2D9CQ35192223-E9C7C24E-D8EE-46EE-9AD0-80CFE2448159Q35212575-36756ACA-251D-49F3-9D20-9B814E3CDDB0Q36050008-C40F410F-1A83-48DF-9B54-97E8A79EDDF7Q36127898-FEFEE7F2-EE7F-41F9-9669-F0018A86E779Q36411863-1CD68147-6935-4628-9106-BE93B56F6896Q37185752-CE8A89B9-81F1-4F36-8361-9E86E0F9F3B7Q37378633-68964654-B3C1-4FC8-A7EB-016ECEF600C8Q37485709-A82B9FCB-B0FC-4821-B82A-EEE0ABBECF84Q37559740-B4A2C3FB-A4AF-41B8-93DC-D6754EBFDF27Q37560208-D6DAB496-859B-4B84-9A91-0B7A0BCE96B8Q37620999-19A7F65C-7799-40DF-A8E7-ABBD32EFD5C3Q37741534-4B24F807-045B-4E13-ADC7-FCD172973F06Q38017203-FE71D714-3B0E-4440-8C2F-0249CDEDD18CQ38097514-086D3669-3196-4870-9EE5-D0E56291FD72Q38112578-A5FA5E25-F22A-48AE-AC7D-79929A6ED926Q38132742-FF6448F3-9372-4A42-A7E1-7594CBEFD0C3Q38289992-54FE7586-EAD8-4D79-97DF-0ABC924E39E2Q38364462-979662D0-002D-478B-B9EF-44361C1BC15BQ38628712-3093E8AE-06D1-4F5D-8620-981001F2C562Q38797038-F5FBF486-AD11-4B17-B77C-EB5C2C5DC8ABQ38905573-E4C0D89A-09DE-439C-95CE-948C1B75C4EFQ38988662-A773CA39-2F30-4766-A1F3-080221366104Q38998638-BE61DC5A-2724-432A-8EAA-B7A330DB5F65Q39029793-3A7688D4-F112-4BE5-9994-63BD553A967CQ39100229-F5045234-5524-4BDE-9816-026C5DB97284Q39185087-08C73FE9-B174-47DF-A57E-0123F3C1BF15Q39203683-FA6645F6-0374-463E-BE90-D99BB017F1C5Q40949460-0D79A806-E5A5-46C1-A26F-706318C7A9AE
P2860
Immunocytokines: a novel class of potent armed antibodies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunocytokines: a novel class of potent armed antibodies.
@en
Immunocytokines: a novel class of potent armed antibodies.
@nl
type
label
Immunocytokines: a novel class of potent armed antibodies.
@en
Immunocytokines: a novel class of potent armed antibodies.
@nl
prefLabel
Immunocytokines: a novel class of potent armed antibodies.
@en
Immunocytokines: a novel class of potent armed antibodies.
@nl
P1433
P1476
Immunocytokines: a novel class of potent armed antibodies.
@en
P2093
Dario Neri
Nadine Pasche
P304
P356
10.1016/J.DRUDIS.2012.01.007
P577
2012-01-24T00:00:00Z